BridgeMD
New treatment option for NSCLC Stage IV Without EGFR/ALK Mutation
Official title Study on the Optimal Combination Pattern of the Combined Treatment of Radiotherapy and Immunotherapy for the Abscopal Effect in Non-Small Cell Lung Cancer (NSCLC) With Multiple Metastases
ClinicalTrials.gov ID: NCT06953843
What this study is testing
What is Benmelstobart combined with chemotherapy?
Benmelstobart combined with chemotherapy is an investigational medicine, being studied as a potential treatment for nsclc stage iv without egfr/alk mutation.
Also referred to as Radiotherapy.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This study aims to conduct a prospective, multicenter, umbrella clinical study to compare the abscopal effects of different radiotherapy fractionation patterns combined with Benmelstobart, and to explore an efficient and low-toxic treatment strategy for non-small cell lung cancer (NSCLC) with multiple metastases. The main objective is to explore and compare the control rates of abscopal lesions in NSCLC patients with multiple metastases when different radiotherapy fractionation patterns are combined with Benmelstobart.
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 75
You may be able to join if
- Patient must meet all of the following to be enrolled in this study:
- Non-small cell lung cancer confirmed by pathological histology.
- More than 3 metastatic lesions.
- No brain metastases or stable lesions.
- Negative for driver genes (including EGFR, ALK, ROS, BRAF, MET, RET).
You likely can't join if
- Patients with any of the following criteria are not eligible for enrollment in this study:
- Those with severe dysfunction of important vital organs (heart, liver, kidney).
- Those accompanied by other malignant tumors.
- Uncontrolled heart diseases or myocardial infarction within the past 6 months.
- Those with a history of mental illness.
- Other situations in which the researcher deems it inappropriate for the subject to participate in the study.
See the full eligibility criteria
- Patient must meet all of the following to be enrolled in this study:
- Non-small cell lung cancer confirmed by pathological histology.
- More than 3 metastatic lesions.
- No brain metastases or stable lesions.
- Negative for driver genes (including EGFR, ALK, ROS, BRAF, MET, RET).
- Performance status (PS) score of 0-1, with an expected survival period of more than 3 months.
- Age between 18 and 75 years old.
- Assessment by PET-CT (including FDG and FMISO, not mandatory).
- No contraindications to immunotherapy and radiotherapy.
- Signed the informed consent form.
- Patients with any of the following criteria are not eligible for enrollment in this study:
- Those with severe dysfunction of important vital organs (heart, liver, kidney).
- Those accompanied by other malignant tumors.
- Uncontrolled heart diseases or myocardial infarction within the past 6 months.
- Those with a history of mental illness.
- Other situations in which the researcher deems it inappropriate for the subject to participate in the study.
The study team makes the final eligibility decision.
Where it's taking place
- Chongqing, Chongqing Municipality, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 75 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Chongqing, Chongqing Municipality, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.